1689.1 – Quantification of NT-proBNP in patients with diagnosed pulmonary arterial hypertension for ongoing risk assessment

Page last updated: 11 October 2023

Application Detail

Description of Medical Service

Measurement of NT-proBNP (also known as N-terminal pro-brain natriuretic peptide, N-terminal pro-B-type natriuretic peptide or N-terminal prohormone of brain natriuretic peptide) through a blood test. The blood test is intended to enable the early detection of systemic sclerosis related pulmonary arterial hypertension, and be used as a regular assessment of pulmonary arterial hypertension disease progression.

Description of Medical Condition

Pulmonary arterial hypertension is characterised by increased pulmonary vascular resistance (resistance against blood flow), and may be idiopathic (arising from an unknown cause), or due to other underlying factors or disease associations such as connective tissue disease.

Reason for Application

At the July 2022 meeting, MSAC considered an application requesting Medicare Benefits Schedule (MBS) listing of N-terminal pro B-type natriuretic peptide (NT-proBNP) biomarker assay for (1) detection of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc), and for (2) risk assessment of patients diagnosed with PAH. After consideration, MSAC supported the creation of a new MBS item for the quantification of laboratory-based NT-proBNP testing for detection of PAH in patients with SSc, but did not support public funding for NT-proBNP testing in patients with an established diagnosis of PAH. Application 1689.1 is a reapplication that aims to address the concerns of MSAC and requests MBS listing for NT-proBNP testing in patients with an established diagnosis of PAH.

Medical Service Type

Investigative technology

Previous Application Number/s


Associated Documentation

Application Summary

An updated application has been received for this resubmission, and a summary of the application is as follows

Application Summary (PDF 527 KB)
Application Summary (Word 53 KB)

Consultation Survey

Consultation Survey (PDF 656 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Bypassing PASC

MSAC Consultation
MSAC consultation input closed Friday, 9 June 2023.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

Not applicable

Assessment Report


Public Summary Document

Public Summary Document (PDF 887 KB)
Public Summary Document (Word 570 KB)

Meetings for this Application


Bypassing PASC


8-9 June 2023


27-28 July 2023